Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIMK1 | P53667 | 2/20 | 0.67 |
| ▸ | MAPT | P10636 | 11/20 | 0.66 |
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.66 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.66 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.66 |
| ▸ | IKBKB | O14920 | 3/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 9/20 | 0.60 |
| ▸ | MEN1 | O00255 | 8/20 | 0.60 |
| ▸ | HPGD | P15428 | 7/20 | 0.60 |
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.60 |
| ▸ | USP2 | O75604 | 2/20 | 0.60 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | FOXM1 | Q08050 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 2/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.57 |
| ▸ | CASP1 | P29466 | 2/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19000418 | 0.90 | LIMK1 (0.66) | LIMK1MAPTKDM4EALDH1A1MAPK1 | |
| SCHEMBL27473523 | 0.90 | HPGD (0.70) | LIMK1MAPTKDM4EALDH1A1MAPK1 | |
| SCHEMBL25891670 | 0.89 | MAPT (0.64) | LIMK1MAPTKDM4EALDH1A1MAPK1 | |
| SCHEMBL18958902 | 0.88 | MAPT (0.64) | LIMK1MAPTKDM4EALDH1A1MAPK1 | |
| SCHEMBL430610 | 0.88 | LIMK1 (0.74) | LIMK1MAPTKDM4EALDH1A1MAPK1 | |
| SCHEMBL23695633 | 0.85 | MAPT (0.80) | LIMK1MAPTKDM4EALDH1A1MAPK1 | |
| SCHEMBL16557519 | 0.85 | MAPT (0.68) | MAPTKDM4EALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL23515691 | 0.85 | MAPT (0.71) | MAPTKDM4EALDH1A1MAPK1L3MBTL1 | |
| SCHEMBL11887880 | 0.84 | MAPT (0.85) | LIMK1MAPTKDM4EALDH1A1MAPK1 | |
| SCHEMBL29932640 | 0.83 | MAPT (0.74) | MAPTKDM4EALDH1A1MAPK1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230226027-A1 | THIENOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CORONAVIRUS INFECTION | UNIVERSITE TOULOUSE III - PAUL SABATIER (FR) | 2023-07-20 | — | — | US | disclosed |
| US-20230030517-A1 | EPAC1 INHIBITORS FOR THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS | UNIVERSITÉ PAUL SABATIER TOULOUSE III (FR) | 2023-02-02 | — | — | US | disclosed |
| WO-2021250231-A1 | THIENOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CORONAVIRUS INFECTION | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2021-12-16 | — | — | WO | disclosed |
| US-20210230179-A1 | THIENO[2,3-B]PYRIDINE DERIVATIVES AS EPAC INHIBITORS AND THEIR PHARMACEUTICAL USES | Universite Paris-Saclay (FR) | 2021-07-29 | — | — | US | disclosed |
| WO-2021116389-A1 | EPAC1 INHIBITORS FOR THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2021-06-17 | — | — | WO | disclosed |
| WO-2019234197-A1 | THIENO[2,3-B]PYRIDINE DERIVATIVES AS EPAC INHIBITORS AND THEIR PHARMACEUTICAL USES | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2019-12-12 | — | — | WO | disclosed |
| US-10301320-B2 | Compositions and methods of modulating 15-PGDH activity | UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION (US) | 2019-05-28 | — | — | US | disclosed |
| US-9790233-B2 | Compositions and methods of modulating 15-PGDH activity | CASE WESTERN RESERVE UNIVERSITY (US) | 2017-10-17 | — | — | US | disclosed |
| US-9790233-B2 | Compositions and methods of modulating 15-PGDH activity | CASE WESTERN RESERVE UNIVERSITY (US) | 2017-10-17 | — | — | US | disclosed |
| EP-3181568-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | Siga Technologies, Inc. (US) | 2017-06-21 | — | — | EP | disclosed |
| US-20150072998-A1 | COMPOSITIONS AND METHODS OF MODULATING 15-PGDH ACTIVITY | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2015-03-12 | — | — | US | disclosed |
| US-20150072998-A1 | COMPOSITIONS AND METHODS OF MODULATING 15-PGDH ACTIVITY | BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2015-03-12 | — | — | US | disclosed |
| WO-2014089378-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECHNOLOGIES, INC. (US) | 2014-06-12 | — | — | WO | disclosed |
| US-20130129677-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | SIGA TECHNOLOGIES, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130129677-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | SIGA TECHNOLOGIES, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130129677-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | SIGA TECHNOLOGIES, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20120022046-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | SIGA TECHNOLOGIES, INC. | 2012-01-26 | — | — | US | disclosed |
| US-20120022046-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | SIGA TECHNOLOGIES, INC. | 2012-01-26 | — | — | US | disclosed |
| US-20120022046-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | SIGA TECHNOLOGIES, INC. | 2012-01-26 | — | — | US | disclosed |
| WO-2010099166-A1 | THIENOPYRIDINE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF DENGUE VIRUS INFECTIONS | SIGA TECHNOLOGIES, INC. (US) | 2010-09-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120022046-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | TTPA, TPMT, SLC19A2 | LIMK1 2427/4885MAPT 138/4885KDM4E 1399/4885 |
| US-20210230179-A1 | THIENO[2,3-B]PYRIDINE DERIVATIVES AS EPAC INHIBITORS AND THEIR PHARMACEUTICAL USES | RAPGEF3, EPAS1, RAPGEF4 | LIMK1 956/4885MAPT 3807/4885KDM4E 1134/4885 |
| US-20230226027-A1 | THIENOPYRIDINE DERIVATIVES FOR USE IN THE TREATMENT OF CORONAVIRUS INFECTION | TRPC1, SARS1, EPAS1 | LIMK1 2612/4885MAPT 3961/4885KDM4E 1370/4885 |
| US-20130129677-A1 | Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections | TTPA, TPMT, SLC19A2 | LIMK1 2446/4885MAPT 85/4885KDM4E 1403/4885 |
| US-20230030517-A1 | EPAC1 INHIBITORS FOR THE TREATMENT OF IDIOPATHIC PULMONARY FIBROSIS | RAPGEF4, RAPGEF3, EPAS1 | LIMK1 2714/4885MAPT 4877/4885KDM4E 624/4885 |
| US-20150072998-A1 | COMPOSITIONS AND METHODS OF MODULATING 15-PGDH ACTIVITY | PTGS1, HPGD, PTGIS | LIMK1 3327/4885MAPT 4311/4885KDM4E 3434/4885 |
| US-10301320-B2 | Compositions and methods of modulating 15-PGDH activity | PTGS1, HPGD, PTGIS | LIMK1 3327/4885MAPT 4311/4885KDM4E 3434/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.